studies

720A AASLD ABSTRACTS HEPATOLOGY, October, 2015
analyzed with MEGA 5.0 software to identify RAVs to nine
DAAs (Boceprevir, Telaprevir, Simeprevir, Paritaprevir, Daclatasvir,
Ledipasvir, Omitasvir, Sofosbuvir and Dasabuvir) in the
HCV genome, which were summarized from the up-to-date
literature available. Results: This analysis collected 1459 fulllength
HCV sequences from GenBank, 70.7% of which carried
at least one dominant resistance variant. Geographically, the
highest RAV frequency occurred in Asia (87.7%), followed
by Africa (73.8%), Europe (69.0%) and America (63.3%).
The highest RAV frequency was observed in genotype (GT) 6
sequences (83.8%), followed by GT2 (83.2%), GT4 (77.6%),
GT1 (67.6%) and GT3 (50.0%). Furthermore, 46.0%, 30.6%
and 10.8% of sequences were observed RAVs to NS5A inhibitors,
NS3 protease inhibitors and their combinations respectively.
However, RAVs to NS5B nucleos(t)ide inhibitor (NI)
and NI-based combinations were uncommon observed (< 3%
of sequences). As expected, RAVs were rare (0.2% to 2.1%)
detected to the IFN-free regimens recommended by the currently
guideline. Conclusion: The global overall prevalence of
DAA-induced RAVs was high without regard for geography or
genotype. Similarly, RAVs to NS5A and NS3 inhibitors were
mainly observed. In contrast, NS5B NI-based multi-DAA regimens
had a low prevalence of RAVs, suggesting that NS5B
NI-based DAA regimens are the most promising strategies for
a long-term HCV infection cure. This result was consistent with
the currently recommended IFN-free regimens.
Disclosures:
The following authors have nothing to disclose: Peng Hu, Zhi-wei Chen, Hu Li,
Hong Ren
SOLAR1 (NCT01938430) and SOLAR 2 (NCT02010255)
studies. On treatment and post-treatment HCV RNA measurements
from LT patients who received CyA or TAC were
compared. Patients who took both or neither of the immunosuppresants
were excluded. Final data for post-treatment Week
12 for SOLAR 2 are pending and will be presented; however,
relapse rates based on post-treatment Week 4 data were calculated.
HCV RNA was measured using the Roche COBAS®
Ampliprep®/Cobas TaqMan HCV Test, Version 2.0 (CAP/
CTM HCV v2.0) with a lower limit of quantification (LLOQ) of
15 IU/mL. Results: A total of 405 post-transplantation patients
were included in the analysis: 309 (76%) patients had received
TACand 96 (24%) had received CyA. The number of patients
with decompensated disease receiving TAC and CyA was 73
(24%) and 22 (23%) respectively. Median, Q1, and Q3 baseline
HCV RNA values were similar among patients receiving
TAC (6.5, 6.0, 6.8) and CyA (6.6, 6.1, 6.9). The percentage
of patients with an HCV RNA < 800,000 IU/mL was 21%
versus 18%, for TAC and CyA. The percent of patients who
were